Inherited metabolic disorders and dyslipidaemia

Sulaiman, Raashda A.

doi:10.1136/jclinpath-2019-205910

Cited by 6 publications

(4 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying causes of hyperlipidemia can be genetic, including familial chylomicronemia syndrome (FCS), familial dysbetalipoproteinemia (FD), familial hypertriglyceridemia (FHTG), homozygous familial hypercholesterolemia (HoFH), or autosomal recessive hypercholesterolemia (ARH). Additionally, secondary causes of dyslipidemia encompass type 2 diabetes mellitus, obesity, chronic renal failure, cholestasis, or the use of medications such as steroids, thiazide diuretics, and selected beta-adrenergic blockers [10]. Hyperlipidemia is a predominant contributor to morbidity and is strongly linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD) [11,12].…”

Section: Dyslipidemia Its Association With Cardiovascular Disease And...mentioning

confidence: 99%

New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets

Wojtasińska,

Kućmierz,

Tokarek

et al. 2023

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) which consist of ischemic heart disease, stroke, heart failure, peripheral arterial disease, and several other cardiac and vascular conditions are one of the most common causes of death worldwide and often co-occur with diabetes mellitus and lipid disorders which worsens the prognosis and becomes a therapeutic challenge. Due to the increasing number of patients with CVDs, we need to search for new risk factors and pathophysiological changes to create new strategies for preventing, diagnosing, and treating not only CVDs but also comorbidities like diabetes mellitus and lipid disorders. As increasing amount of patients suffering from CVDs, there are many therapies which focus on new molecular targets like proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like protein 3, ATP-citrate lyase, or new technologies such as siRNA in treatment of dyslipidemia or sodium-glucose co-transporter-2 and glucagon-like peptide-1 in treatment of diabetes mellitus. Both SGLT-2 inhibitors and GLP-1 receptor agonists are used in the treatment of diabetes, however, they proved to have a beneficial effect in CVDs as well. Moreover, a significant amount of evidence has shown that exosomes seem to be associated with myocardial ischaemia and that exosome levels correlate with the severity of myocardial injury. In our work, we would like to focus on the above mechanisms. The knowledge of them allows for the appearance of new strategies of treatment among patients with CVDs.

show abstract

Section: Dyslipidemia Its Association With Cardiovascular Disease And...mentioning

confidence: 99%

New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets

Wojtasińska,

Kućmierz,

Tokarek

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Elevated LDL levels are implicated in the development of cardiovascular diseases, while hypertriglyceridemia is linked to nonalcoholic fatty liver disease and acute pancreatitis. The TG/HDL ratio is recognized as a marker for metabolic syndrome (Ryan et al, 2018;Sulaiman, 2020;Pirillo et al, 2021). Lipid metabolism also plays a significant role in modulating immune responses, with implications for T cells, macrophages, dendritic cells, and other immune cell types in diseases such as nonalcoholic fatty liver disease, pancreatic fibrosis, and cancer progression (Yan and Horng, 2020;Liu et al, 2021;Yu et al, 2021;Lim et al, 2022;Zhao et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Exploring blood lipids-immunity associations following HBV vaccination: evidence from a large cross-sectional study

Yang,

Li,

Luan

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionSerological responses following hepatitis B vaccination are crucial for preventing hepatitis B (HBV). However, the potential relationship between serum lipid levels and immunity from HBV vaccination remains poorly understood.MethodsIn this study, we conducted an analysis of the National Health and Nutrition Examination Survey (NHANES) data spanning from 2003 to 2016. Multivariable weighted logistic regression models, generalized linear analysis, stratified models, smooth curve fitting, segmentation effect analysis and sensitivity analysis were utilized to assess the relationships.ResultsAfter adjusting for relevant covariates, we observed that low levels of high-density lipoprotein cholesterol (HDL) were independently linked to a significantly lower seroprotective rate. Compared to HDL levels of ≥ 60 mg/dL, the odds ratios (ORs) for individuals with borderline levels (40-59 mg/dL for men, 50-59 mg/dL for women) and low levels (< 40 mg/dL for men, < 50 mg/dL for women) were 0.83 (95% CI 0.69-0.99) and 0.65 (95% CI 0.56-0.78), respectively. This association was particularly pronounced in individuals aged 40 or older. Conversely, higher levels of the triglyceride to HDL (TG/HDL) ratio (OR, 0.90; 95% CI, 0.84-0.98), total cholesterol to HDL (Chol/HDL) ratio (OR, 0.77; 95% CI, 0.64-0.92), and low-density lipoprotein to HDL (LDL/HDL) ratio (OR, 0.85; 95% CI, 0.76-0.96) were associated with a decreased likelihood of seroprotection.ConclusionThis study suggests that lipid levels may play a role in modulating the immune response following HBV vaccination.

show abstract

“…This lipid alteration has various etiologies that can be divided into primary and secondary. The first group consists of genetic diseases, such as familial chylomicronemia syndrome (FCS), familial dysbetalipoproteinemia (FD), familial hypertriglyceridemia (FHTG), homozygous familial hypercholesterolemia (HoFH), autosomal recessive hypercholesterolemia (ARH), et cetera, while the second group includes functioning disorders of specific organs, namely the kidneys, thyroid gland, and liver, or disorders that may occur due to taking certain medications like steroids or selected beta-adrenergic blockers [2]. What is more, a sedentary lifestyle and unhealthy diet also have their own role in dyslipidemia development, even among the youth [3].…”

Section: Introductionmentioning

confidence: 99%

Advances in Treatment of Dyslipidemia

Dybiec,

Baran,

Dąbek

et al. 2023

IJMS

View full text Add to dashboard Cite

Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.

show abstract

Inherited metabolic disorders and dyslipidaemia

Cited by 6 publications

References 78 publications

New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets

New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets

Exploring blood lipids-immunity associations following HBV vaccination: evidence from a large cross-sectional study

Advances in Treatment of Dyslipidemia

Contact Info

Product

Resources

About